NCT01263353View on ClinicalTrials.gov

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Interventions
DRUG

Pasireotide LAR followed by Pasireotide LAR + Everolimus

DRUG

Everolimus followed by Pasireotide LAR + Everolimus

Trial Locations (4)

13353

Novartis Investigative Site, Berlin

35039

Novartis Investigative Site, Marburg

48149

Novartis Investigative Site, Münster

99438

Novartis Investigative Site, Bad Berka

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY